Celgene Corporation, Senior Advisor and Former Chairman
Dr. Barer spent most of his professional career with the Celgene Corporation, one of the fastest growing and most profitable global biopharmaceutical companies with a market capitalization of ~$30 Billion, products in over 70 countries and revenues expected to exceed $4 Billion this year. He was Chairman of Celgene from January 2011 until June 2011, Executive Chairman from June 2010 until Jan 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Read more »
Chairman: Sol Barer, Ph.D
Immediate Past Chair: Geert Cauwenbergh, Ph.D.
Phases 123 LLC, Managing Director
Dr. Cauwenbergh founded Phases 123 LLC, a company focused on identifying high potential health care technology platforms and emerging health care companies. Read more »
President: Debbie Hart, CAE, APR
BioNJ, President
Debbie Hart serves as the President of BioNJ. She worked alongside New Jersey’s leading biotechnology industry CEOs to establish BioNJ in 1994. Read more »
Vice Chairman: Christopher J. Schaber, Ph.D.
Soligenix, Inc., President and CEO
Christopher J. Schaber, Ph.D., has over 20 years experience in both big pharma and start-up biotech. He has been Soligenix’s President Read more »
Secretary: Richard Kender
Merck & Co., Inc., Senior Vice President, Business Development & Corporate Licensing
Mr. Kender is responsible for Corporate Development, Corporate Licensing, Human Health Business Development, U.S.H.H. Business Development and Financial Evaluation and Analysis. Read more »
Treasurer: Francois Nader, M.D., M.B.A.
NPS Pharmaceuticals, Inc., President & CEO
Dr. Francois Nader has been President and CEO of NPS since March 2008. Dr. Nader joined NPS in June 2006 and served as executive vice president and chief operating officer Read more »
